Codexis

Codexis Current Liabilities

The Current Liabilities of Codexis (CDXS) as of Sep 26, 2026 is 18.31 M USD. In the previous year, Current Liabilities was 43.76 M USD — a change of -58.16% (lower).

Current Liabilities

18.31 MUSD

YoY

-58.16%

Last updated:

Current Liabilities of Codexis is 2026 18.31 M USD. Current Liabilities of Codexis was 2025 43.76 M USD. It decreases by -58.16% lower compared to the previous year.

The Codexis Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
22.58 M USD
Jan 1, 2019
28.13 M USD
Jan 1, 2020
43.36 M USD
Jan 1, 2021
58.59 M USD
Jan 1, 2022
67.44 M USD
Jan 1, 2023
45.47 M USD
Jan 1, 2024
43.76 M USD
Jan 1, 2025
18.31 M USD
The Codexis Current Liabilities history
YEARCurrent LiabilitiesYoY
18.31 MUSD-58.16%
43.76 MUSD-3.77%
45.47 MUSD-32.57%
67.44 MUSD+15.11%
58.59 MUSD+35.12%
43.36 MUSD+54.13%
28.13 MUSD+24.60%
22.58 MUSD+7.20%
21.06 MUSD+27.97%
16.46 MUSD+17.45%
14.01 MUSD-11.53%
15.84 MUSD+9.99%
14.40 MUSD-41.22%
24.50 MUSD-36.54%
38.60 MUSD+5.34%
36.65 MUSD-34.42%
55.88 MUSD+12.61%
49.62 MUSD+13.11%
43.87 MUSD+191.57%
15.04 MUSD—
Access this data via the Eulerpool API

Codexis Stock analysis

What does Codexis do? Codexis Inc. is an American biotechnology company that specializes in developing innovative biological solutions for a variety of industries. The company was founded in 2002 and is headquartered in Redwood City, California. Business Model: Codexis is service-oriented and provides customized enzyme solutions for companies looking to improve their products through sustainable processes. The company has developed a unique platform called Rational Protein Engineering, which allows for the development of specific enzymes for various industries. Customers benefit from enzyme optimization expertise and know-how. Divisions: Codexis operates in the fields of life sciences, materials science, agrochemicals, and biofuels. 1. Life Sciences: Codexis specializes in the production of enzymes and biocatalysts for the pharmaceutical industry in the life sciences division. The goal is to provide a faster and more efficient manufacturing process for pharmaceutical active ingredients. The company has successfully developed active ingredients for antibodies, lipids, uric acid, and antivirals. 2. Materials Science: In the materials science division, Codexis specializes in the production of enzymes for materials such as dyes, polymers, and cosmetic products. Codexis ensures that these products are efficiently manufactured without the use of environmentally harmful chemicals. 3. Agrochemicals: Codexis offers customized enzyme solutions to agrochemical manufacturers that reduce the use of chemicals and benefit the environment. These enzymes help in the production of pesticides and other agrochemicals. 4. Biofuels: In the biofuels division, Codexis specializes in the production of enzymes for processing corn, harvested plants, or waste products. These enzymes help enable cost-effective biofuel production. Products: Codexis has developed a wide range of products tailored to the needs of various industries. Some of the products recently introduced to the market by Codexis include: 1. CodeEvolver: CodeEvolver is a platform that allows biotechnology companies to quickly create customized enzyme solutions for their specific needs. The process is fully automated and results in a significant reduction in development time and costs. 2. Codex® screening panels: Codexis offers various screening panels that allow customers to quickly and efficiently select the enzymes best suited for their purposes. The panels are suitable for industries including pharmaceuticals, chemicals, and plant protection. 3. Codex® enzymes: Codexis offers a wide range of enzymes specifically designed for different industry needs. This includes enzymes for the production of biofuels, pesticides, cosmetic products, and pharmaceuticals. Overall, Codexis Inc. has demonstrated its ability to deepen the understanding of biocatalysts and introduce innovative biological processes in a variety of industries through its unique Rational Protein Engineering platform. Codexis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Codexis stock

Current Liabilities of Codexis is 18.31 M USD in 2026.

Current Liabilities of Codexis changed from 43.76 M USD to 18.31 M USD, representing a -58.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Codexis since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Codexis historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Codexis

All Key Metrics — Codexis